Results 11 to 20 of about 2,249 (191)

Budget Impact Analysis of Lebrikizumab for Treating Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Lebrikizumab is a novel monoclonal antibody that targets interleukin-13, a pivotal factor in atopic dermatitis (AD). Previous studies revealed a positive benefit–risk profile of lebrikizumab as treatment for patients with moderate-to-severe ...
Ippazio Cosimo Antonazzo, Giampiero Girolomoni, Cataldo Patruno, Roberto Langella, Veronica Ottobrino, Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi   +6 more
doaj   +7 more sources

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Dermatology and Therapy, 2023
Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Angela J Okragly, Chetan N Patel, Robert J Benschop   +2 more
exaly   +4 more sources

Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) [PDF]

Dermatology and Therapy
Introduction The efficacy and safety of lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, were investigated in patients with moderate-to-severe atopic dermatitis (AD) up to 52 weeks in phase 3 trials.
Emma Guttman-Yassky, Stephan Weidinger, Diamant Thaçi   +2 more
exaly   +3 more sources

Lebrikizumab-induced psoriasis in a patient with atopic dermatitis [PDF]

JAAD Case Reports
Marley Cutrona, BS, Alexandra K. Golant, MD   +1 more
doaj   +5 more sources

Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

Clinical and Translational Allergy, 2022
Background Lebrikizumab is a monoclonal antibody that modulates activity of interleukin‐13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard‐of‐care treatment.
Stanley J Szefler, Graham Roberts, Piotr Kuna   +2 more
exaly   +2 more sources

Retrospective Analysis of Lebrikizumab in the Management of Atopic Dermatitis: Insights from Real-World Practice [PDF]

Dermatology and Therapy
Introduction  Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease, significantly impacting a patient’s quality of life. To date, a substantial proportion of patients present an insufficient response to available treatment options ...
Nikolaos Stavropoulos, Daniel Myszkowski, Dennis Braß, Vasileios Dervenis, Effimia Poungoura, Eggert Stockfleth   +5 more
doaj   +2 more sources

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study [PDF]

Dermatology and Therapy
Introduction Patients with moderate-to-severe atopic dermatitis (AD) who discontinue dupilumab need additional therapeutic options. Lebrikizumab’s distinct mechanism of action may provide that alternative treatment.
Jonathan I. Silverberg, Lindsay Ackerman, Jerry Bagel, Linda Stein Gold, Andrew Blauvelt, David Rosmarin, Raj Chovatiya, Matthew Zirwas, Gil Yosipovitch, Jill Waibel, Jenny E. Murase, Ben Lockshin, Jamie Weisman, Amber Reck Atwater, Jennifer Proper, Maria Silk, Evangeline Pierce, Maria Lucia Buziqui Piruzeli, Sonia Montmayeur, Christopher Schuster, Jinglin Zhong, Maria Jose Rueda, Sreekumar Pillai, Eric Simpson   +23 more
doaj   +2 more sources

Atopic Dermatitis Successfully Treated with Lebrikizumab in Real-World Clinical Practice in Czech Republic: A Case Series [PDF]

Dermatology and Therapy
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with impaired quality of life and a substantial burden of disease. Lebrikizumab is a monoclonal antibody that selectively binds with high affinity to interleukin-13, thereby ...
Marie Jandová, Radek Litvik, Martin Tichý, Spyridon Gkalpakiotis   +3 more
doaj   +2 more sources

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis [PDF]

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a chronic skin disease largely driven by interleukin (IL)-13, which is targeted by tralokinumab and lebrikizumab.
Matthias Augustin, April Armstrong, Naiem T. Issa, Anne Sohrt Petersen, Rie von Eyben, Teodora Festini, Tiago Torres   +6 more
doaj   +2 more sources

Lebrikizumab for the Treatment of Moderate to Severe Atopic Eczema: Real-World Experience from a Tertiary Centre [PDF]

Dermatology and Therapy
Introduction Lebrikizumab, a human monoclonal antibody that targets interleukin-13, is approved for treating moderate to severe atopic dermatitis in many regions.
Azmeralda Abraheem, Neenu Sebastian, Firas C. Kreeshan, Tim H. Clayton, Hamish J. A. Hunter, Richard B. Warren   +5 more
doaj   +2 more sources